Radiation plus two medicines for high-risk soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70 and expected to live more than 2 years
- Your sarcoma diagnosis is confirmed by pathology, and it is grade 2 or 3
- Your scans show a localized tumor in an arm/leg or the trunk, with no spread to distant organs
- The tumor is either larger than 5 cm, borderline resectable/unresectable, or it has returned after surgery
- You can have treatment with good performance status (about fully active or limited activity), and your blood/organ/clotting tests are in acceptable ranges before starting
- You have not had certain recent treatments: no other chemotherapy/targeted therapy in the last 4 weeks, and no prior anti-PD1 immunotherapy
- You are not pregnant/breastfeeding, and you have no allergies to any study drug ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
This trial tests a combination of radiation therapy and two drugs (anlotinib and penpulimab) given before surgery for soft tissue sarcoma. The goal is to see if this approach can shrink tumors and improve outcomes.
This Phase 2 trial tests whether giving radiation before surgery, along with anlotinib and penpulimab, can improve treatment for localized soft tissue sarcoma. It may help shrink or control the tumor before conservative surgery.
This trial tests a new way of giving radiation therapy (called spatially fractionated radiotherapy) combined with a treatment strategy called PraG (pembrolizumab and granulocyte-macrophage colony-stimulating factor) for people with soft tissue sarcoma that cannot be removed or has spread. The goal is to see if the combination can help shrink or control the cancer.
This trial tests a personalized (“adaptive”) radiation plan before surgery for high-grade soft-tissue sarcoma that can be removed. It may help shrink the tumor and improve how well surgery can treat the cancer.
This trial tests a newer way of giving radiation (spatially fractionated) compared to standard radiation for people with large soft tissue sarcomas. It aims to see if the new method works better.
Hear when a new High-Risk Localized Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.